Actinium-225 DOTA TLX 592

N/A

Report date: 2025/10/23 14:12:14

Base Information

Drug NameActinium-225 DOTA TLX 592

Drug Alias NameTLX-592225-Ac-RADmAb225Ac-DOTA-TLX 592225Ac-TLX 592

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radionuclide Drug Conjugates +[4]

Mechanisms of ActionPositron-emission tomography enhancersRadionuclide imaging enhancersProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesTelix Pharmaceuticals Ltd

China Registration ClassN/A

Develop Information

Active CompaniesTelix Pharmaceuticals Ltd

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A